Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

NCT00282087 ↗

Phase 2 Completed 47 enrolled Sarcoma Alliance for Research through Collaboration

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.

Timeline

Start: 2006-01
Primary completion: 2012-01
Completion: 2012-01

Publications

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013 Apr 15;119(8):1555-61. doi: 10.1002/cncr.27942. Epub 2013 Jan 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	60 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	900 mg/m2	Intravenous

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Summary

Timeline

Publications

Drugs

Indications